Cited by 402Muscle Physiology and DisordersAdipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

The DOI matches its Crossref record; 49 of the 51 references it cites were found in a registry or an index.

Myostatin Inhibition in Muscle, but Not Adipose Tissue, Decreases Fat Mass and Improves Insulin Sensitivity

Open access

Abstract

Myostatin (Mstn) is a secreted growth factor expressed in skeletal muscle and adipose tissue that negatively regulates skeletal muscle mass. Mstn(-/-) mice have a dramatic increase in muscle mass, reduction in fat mass, and resistance to diet-induced and genetic obesity. To determine how Mstn deletion causes reduced adiposity and resistance to obesity, we analyzed substrate utilization and insulin sensitivity in Mstn(-/-) mice fed a standard chow. Despite reduced lipid oxidation in skeletal muscle, Mstn(-/-) mice had no change in the rate of whole body lipid oxidation. In contrast, Mstn(-/-) mice had increased glucose utilization and insulin sensitivity as measured by indirect calorimetry, glucose and insulin tolerance tests, and hyperinsulinemic-euglycemic clamp. To determine whether these metabolic effects were due primarily to the loss of myostatin signaling in muscle or adipose tissue, we compared two transgenic mouse lines carrying a dominant negative activin IIB receptor expressed specifically in adipocytes or skeletal muscle. We found that inhibition of myostatin signaling in adipose tissue had no effect on body composition, weight gain, or glucose and insulin tolerance in mice fed a standard diet or a high-fat diet. In contrast, inhibition of myostatin signaling in skeletal muscle, like Mstn deletion, resulted in increased lean mass, decreased fat mass, improved glucose metabolism on standard and high-fat diets, and resistance to diet-induced obesity. Our results demonstrate that Mstn(-/-) mice have an increase in insulin sensitivity and glucose uptake, and that the reduction in adipose tissue mass in Mstn(-/-) mice is an indirect result of metabolic changes in skeletal muscle. These data suggest that increasing muscle mass by administration of myostatin antagonists may be a promising therapeutic target for treating patients with obesity or diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0004937

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Substrate utilization in Mstn+/+ and Mstn−/− mice on standard chow. (A) Total respiratory exchange ratio determined by indirect calorimetry. (B) Amount of palmitate oxidized per soleus muscle. (C) Amount of palmitate oxidized by soleus muscle normalized to soleus mass. (D) Rate of oleic acid oxidation per mouse. (E) Rate of oleic acid oxidation normalized to lean mass. n = 6–10. *P<0.05, **P<0.01, ***P<0.001.
Figure 1 Substrate utilization in Mstn+/+ and Mstn−/− mice on standard chow. (A) Total respiratory exchange ratio determined by indirect calorimetry. (B) Amount of palmitate oxidized per soleus muscle. (C) Amount of palmitate oxidized by soleus muscle normalized to soleus mass. (D) Rate of oleic acid oxidation per mouse. (E) Rate of oleic acid oxidation normalized to lean mass. n = 6–10. *P<0.05, **P<0.01, ***P<0.001.CC0 · PubMed Central
Figure 2 Mstn−/− mice have increased insulin sensitivity and reduced weight gain on standard chow and HFD. (A) Blood glucose levels during GTT of Mstn+/+ and Mstn−/− mice on standard chow or HFD. n = 8–16. (B) Percent of starting glucose during ITT of Mstn+/+ and Mstn−/− mice on standard chow or HFD. n = 6–10. (C) Blood glucose (left panel) and insulin (right panel) 0 and 30 minutes after glucose injection in fasted mice maintained on standard chow. n = 6. (D) Body weight gained by Mstn+/+ and Mstn−/− mice after 10 weeks on diets. n = 7–16. *P<0.05, **P<0.01, ***P<0.001. A and B, P value symbols are for comparisons between genotypes on the same diet; below curves, mice on standard chow; above curves, mice on HFD.
Figure 2 Mstn−/− mice have increased insulin sensitivity and reduced weight gain on standard chow and HFD. (A) Blood glucose levels during GTT of Mstn+/+ and Mstn−/− mice on standard chow or HFD. n = 8–16. (B) Percent of starting glucose during ITT of Mstn+/+ and Mstn−/− mice on standard chow or HFD. n = 6–10. (C) Blood glucose (left panel) and insulin (right panel) 0 and 30 minutes after glucose injection in fasted mice maintained on standard chow. n = 6. (D) Body weight gained by Mstn+/+ and Mstn−/− mice after 10 weeks on diets. n = 7–16. *P<0.05, **P<0.01, ***P<0.001. A and B, P value symbols are for comparisons between genotypes on the same diet; below curves, mice on standard chow; above curves, mice on HFD.CC0 · PubMed Central
Figure 3 Mstn−/− mice have increased glucose uptake by hyperinsulinemic-euglycemic clamp. (A) Plasma glucose concentration before and during clamp. Insulin was infused at time 0. (B) Glucose infusion rate during clamp. Glucose uptake in (C) whole body, (D) skeletal muscle, (E) WAT, and (F) BAT. n = 7–8. *P<0.05, ***P<0.001.
Figure 3 Mstn−/− mice have increased glucose uptake by hyperinsulinemic-euglycemic clamp. (A) Plasma glucose concentration before and during clamp. Insulin was infused at time 0. (B) Glucose infusion rate during clamp. Glucose uptake in (C) whole body, (D) skeletal muscle, (E) WAT, and (F) BAT. n = 7–8. *P<0.05, ***P<0.001.CC0 · PubMed Central
Figure 4 Insulin-stimulated activation of Akt by Western blot. In vivo total Akt and phospho-Akt in gastrocnemius muscle, WAT, and BAT from Mstn+/+ and Mstn−/− mice with or without insulin stimulation. Each lane contains protein from a different animal.
Figure 4 Insulin-stimulated activation of Akt by Western blot. In vivo total Akt and phospho-Akt in gastrocnemius muscle, WAT, and BAT from Mstn+/+ and Mstn−/− mice with or without insulin stimulation. Each lane contains protein from a different animal.CC0 · PubMed Central
Figure 5 Tissue-specific inhibition of myostatin signaling. (A) Diagram of the construct used to make fat-DN transgenic mice with the aP2 promoter controlling expression of a truncated Acvr2b containing the extracellular ligand binding and transmembrane domains. (B) Northern blot analysis of expression of fat-DN transgene and Gapdh loading control from different tissues from non-transgenic (−) and transgenic (+) mice. Body composition of (C) fat-DN (n = 10–11) and (D) muscle-DN (n = 5) male mice compared to non-transgenic littermates. Lean and fat mass are shown as absolute values. Body weight gained by (E) fat-DN (n = 9–17) and (F) muscle-DN (n = 9–14) male mice and littermate controls after 10 weeks on diets. Blood glucose levels during GTT of (G) fat-DN (n = 7–8) and (H) muscle-DN (n = 9–14) male mice and littermate controls on standard chow and HFD. Percent of starting glucose during ITT of (I) fat-DN (n = 7–8) and (J) muscle-DN (n = 9–12) male mice and littermate controls on standard chow and HFD. *P<0.05, **P<0.01, ***P<0.001. G–J, P value symbols are for comparisons between genotypes on the same diet; below curves, mice on standard chow; above curves, mice on HFD.
Figure 5 Tissue-specific inhibition of myostatin signaling. (A) Diagram of the construct used to make fat-DN transgenic mice with the aP2 promoter controlling expression of a truncated Acvr2b containing the extracellular ligand binding and transmembrane domains. (B) Northern blot analysis of expression of fat-DN transgene and Gapdh loading control from different tissues from non-transgenic (−) and transgenic (+) mice. Body composition of (C) fat-DN (n = 10–11) and (D) muscle-DN (n = 5) male mice compared to non-transgenic littermates. Lean and fat mass are shown as absolute values. Body weight gained by (E) fat-DN (n = 9–17) and (F) muscle-DN (n = 9–14) male mice and littermate controls after 10 weeks on diets. Blood glucose levels during GTT of (G) fat-DN (n = 7–8) and (H) muscle-DN (n = 9–14) male mice and littermate controls on standard chow and HFD. Percent of starting glucose during ITT of (I) fat-DN (n = 7–8) and (J) muscle-DN (n = 9–12) male mice and littermate controls on standard chow and HFD. *P<0.05, **P<0.01, ***P<0.001. G–J, P value symbols are for comparisons between genotypes on the same diet; below curves, mice on standard chow; above curves, mice on HFD.CC0 · PubMed Central
Figure 6 Adaptation to increased muscle mass. (A) Relative mRNA expression levels in liver of Pepck, G6Pase, Cpt1, Acadm, and Scd1 measured by quantitative RT-PCR in Mstn+/+ and Mstn−/− mice on standard chow or HFD. (B) Serum glucagon, (C) lactate, and (D) β-hydroxybutyrate levels in Mstn+/+ and Mstn−/− mice on standard chow and HFD. n = 6–12. *P<0.05, **P<0.01.
Figure 6 Adaptation to increased muscle mass. (A) Relative mRNA expression levels in liver of Pepck, G6Pase, Cpt1, Acadm, and Scd1 measured by quantitative RT-PCR in Mstn+/+ and Mstn−/− mice on standard chow or HFD. (B) Serum glucagon, (C) lactate, and (D) β-hydroxybutyrate levels in Mstn+/+ and Mstn−/− mice on standard chow and HFD. n = 6–12. *P<0.05, **P<0.01.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 402

Metadata

Authors
Guo, T., Jou, W., Chanturiya, T., Portas, J., Gavrilova, O., & McPherron, A. C.
Affiliations
National Institutes of Health (US)
Corresponding author
McPherron, Alexandra C.
Venue
PLoS ONE
Published
2009-03-19
Volume
4
Issue
3
Pages
e4937
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2028966038
Cited by
402
References
51
Citations by year
2026: 17 · 2025: 18 · 2024: 20 · 2023: 17 · 2022: 27 · 2021: 31 · 2020: 23 · 2019: 25 · 2018: 15 · 2017: 23 · 2016: 17 · 2015: 28 · 2014: 27 · 2013: 29 · 2012: 27
FWCI
11.40
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Johns Hopkins University
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
myostatin, Mstn knockout mice, skeletal muscle, adipose tissue, fat mass, insulin sensitivity, glucose metabolism, lipid oxidation, diet-induced obesity, obesity resistance, muscle mass, high-fat diet, diabetes treatment
MeSH terms
Adipose Tissue, Animals, Diet, Dietary Fats, Glucose, Humans, Insulin, Insulin Resistance, Male, Mice, Inbred C57BL, Oxidation-Reduction, Glucose Clamp Technique, Signal Transduction, Mice, Knockout, Muscle, Skeletal, Lipid Metabolism, Proto-Oncogene Proteins c-akt, Mice, Myostatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review